Gene Expression Profiling in Multiple Myeloma: Implications for Practice
Release Date: November 10, 2016
Expiration Date: November 10, 2017
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Advances in gene expression profiling (GEP) for patients with multiple myeloma have identified gene signatures that aid in risk assessment, disease prognostication, and possible treatment selection. In this activity, Dr. Rafael Fonseca will explain the utility of GEP for risk stratification and disease prognostication, as well as the role of GEP among traditional risk assessment tools, such as the revised International Staging System (R-ISS). In addition, Dr. Fonseca will describe the potential for treatment selection and individualized therapy based on specific investigational gene signatures.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in gene expression profiling.
Upon completion of this educational activity, participants should be able to:
- Recognize genetic signatures associated with varying levels of risk in patients with multiple myeloma
- Explain the interplay between gene expression profiling (GEP) and traditional risk assessment and prognostication tools
- Describe the utility of GEP for treatment selection and identify gene signatures under investigation for correlative therapies
Gene Expression Profiling in Multiple Myeloma: Implications for Practice – Rafael Fonseca, MD
Instructions for Participation and Credit
This activity is eligible for credit through November 10, 2017. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Rafael Fonseca, MD
Getz Family Professor of Cancer and Professor of Medicine
Mayo Clinic Distinguished Investigator
Chair, Department of Medicine
Dr. Rafael Fonseca earned his medical degree at Universidad Anahuac, Mexico. He completed a residency in internal medicine at the University of Miami, and a fellowship in hematology and medical oncology at Mayo Graduate School of Medicine, Rochester. He is the Getz Family Professor of Cancer and a Professor of Medicine. In addition, Dr. Fonseca is a consultant in the Division of Hematology/Oncology at the Mayo Clinic, and Chair of the Department of Medicine. He is also a clinical investigator for the Damon Runyon Cancer Research Fund and has an adjunct academic appointment at the Translational Genomics Research Institute (TGen).
Dr. Fonseca holds membership in the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the International Myeloma Society. He serves as a reviewer/editor for Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and The New England Journal of Medicine, among others. Dr. Fonseca has given many national and international presentations as a visiting professor, and has authored more than 200 articles, book chapters, editorials, abstracts, and letters. He is a frequent reviewer of grants and sits on the SPORE grant review panel.
Throughout his training and career, Dr. Fonseca has received numerous awards and honors. Most notably, he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. His practice has focused on the diagnosis and treatment of plasma cell disorders and its impact on patients. In his laboratory, Dr. Fonseca has led his team of researchers in concentrating on the genetic nature of the clonal cells of plasma cell disorders. He is also interested in myeloma bone disease, prognostic markers, and development of new therapies.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-119-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Rafael Fonseca has received consultant fees from Amgen, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, Sanofi, and Takeda Oncology. He has received grant support related to research activities from Applied Biosciences, Cylene Pharmaceuticals, and Onyx. Dr. Fonseca has received a patent for prognostication of multiple myeloma based on genetic categorization by FISH, and has a patent pending for use of calcium isotopes as biomarkers for bone metabolisms.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Physician Payments, Sunshine Act
MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.